Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Wolff

Showing results (621-630 of 831) with videos related to

Pageof 84
Sort By:
Contemporary Clinical Trials|November 20, 2025
Improving CDK4/6 inhibitors adherence in breast cancer using the CONnected CUstomized Treatment Platform (CONCURxP) mobile health intervention: Study protocol for ECOG-ACRIN EAQ221CDGelareh Sadigh, Fenghai Duan, Ilana F Gareen, et al.
Breast Cancer Research and Treatment|June 11, 2008
The impact of sharing results of a randomized breast cancer clinical trial with study participantsAnn H Partridge, A C Wolff, P K Marcom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2008
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneHarold J Burstein, Anthony D Elias, Hope S Rugo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profileAntonio C Wolff, Ross C Donehower, M Katherine Carducci, et al.
Clinical Breast Cancer|February 6, 2010
Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancerSaranya Chumsri, Stacie Jeter, Lisa K Jacobs, et al.
BMC Genomics|February 6, 2016
A betabaculovirus encoding a gp64 homologDaniel M P Ardisson-Araújo, Bruna T Pereira, Fernando L Melo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2019
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORxFabrice Andre, Nofisat Ismaila, N Lynn Henry, et al.
Scientific Reports|June 11, 2016
The complete genome of a baculovirus isolated from an insect of medical interest: Lonomia obliqua (Lepidoptera: Saturniidae)C W Aragão-Silva, M S Andrade, D M P Ardisson-Araújo, et al.
Breast (Edinburgh, Scotland)|March 10, 2023
Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trialsLaura Pala, Tommaso De Pas, Eleonora Pagan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2009
African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white womenAni Balmanoukian, Zhe Zhang, Stacie Jeter, et al.
Pageof 84

Showing results (621-630 of 831) with videos related to

Sort By:
Pageof 84
Contemporary Clinical Trials|November 20, 2025
Improving CDK4/6 inhibitors adherence in breast cancer using the CONnected CUstomized Treatment Platform (CONCURxP) mobile health intervention: Study protocol for ECOG-ACRIN EAQ221CDGelareh Sadigh, Fenghai Duan, Ilana F Gareen, et al.
Breast Cancer Research and Treatment|June 11, 2008
The impact of sharing results of a randomized breast cancer clinical trial with study participantsAnn H Partridge, A C Wolff, P K Marcom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2008
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneHarold J Burstein, Anthony D Elias, Hope S Rugo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profileAntonio C Wolff, Ross C Donehower, M Katherine Carducci, et al.
Clinical Breast Cancer|February 6, 2010
Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancerSaranya Chumsri, Stacie Jeter, Lisa K Jacobs, et al.
BMC Genomics|February 6, 2016
A betabaculovirus encoding a gp64 homologDaniel M P Ardisson-Araújo, Bruna T Pereira, Fernando L Melo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2019
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORxFabrice Andre, Nofisat Ismaila, N Lynn Henry, et al.
Scientific Reports|June 11, 2016
The complete genome of a baculovirus isolated from an insect of medical interest: Lonomia obliqua (Lepidoptera: Saturniidae)C W Aragão-Silva, M S Andrade, D M P Ardisson-Araújo, et al.
Breast (Edinburgh, Scotland)|March 10, 2023
Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trialsLaura Pala, Tommaso De Pas, Eleonora Pagan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2009
African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white womenAni Balmanoukian, Zhe Zhang, Stacie Jeter, et al.
Pageof 84